Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

Not Applicable

• Conditions: Hemodialysis
• Interventions: Other: PTA alone without use of the GORE VIABAHN; Device: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface

• Registration Number: NCT01271881
• Lead Sponsor: American Access Care

Brief Summary

Balloon angioplasty is used to open up a narrowing that forms in hemodialysis fistula. Two areas of particular problems are the terminal portion of the cephalic vein near the shoulder and the central veins in the chest. Although angioplasty is standard of care the treated narrowed segments of vein mostly renarrow within 3 months requiring retreatment to keep your dialysis access functional. Recently there has been introduction of a new technology called a covered stent graft. Initial studies suggest that placing this device across the area of narrowing leads to dialysis access staying open longer and needing less angioplasty treatments.

This study is designed to compare angioplasty (standard of care) versus using a covered stent graft. The investigators will then look at the dialysis records and future fistulograms to see if there is decreased flow through the fistula at 3, 6 and 12 months after the initial procedure.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-10
• Study First Submitted: 2010-12-01
• Status Verified: 2011-01
• Study First Submitted QC: 2011-01-06
• Last Update Submitted: 2011-01-06
• Study First Posted: 2011-01-07
• Last Update Posted: 2011-01-07
• Primary Completion: 2011-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

1. Hemodialysis patient with a mature forearm or upper arm access that was created > 2 months before enrollment in study.
2. The patient is ≥ 18 years of age.
3. The patient has a reasonable expectation of remaining on hemodialysis for 12 months.
4. The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements.
5. The patient or his/her legal guardian is willing to provide informed consent.
6. The patient has lesions that meet the angiographic inclusion / exclusion criteria and induce clinical, hemodynamic or functional abnormality.

Exclusion Criteria

1. The patient has a known or suspected systemic infection.
2. The patient has a known or suspected infection of the hemodialysis access and / or bacteremia.
3. The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide.
4. The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease).
5. The patient has known sensitivity to heparin.
6. The patient is scheduled for a live donor kidney transplant.
7. The patient is enrolled in another investigational study or another access maintenance trial
8. The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements
9. Life expectancy is ≤ 24 months.
10. The patient has an untreatable allergy to radiographic contrast material.
11. The patient is pregnant.
12. In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment.
13. The patient's access is planned to be abandoned within 1 year.
14. The patient has indwelling catheters (dialysis, pacemakers, ports).
15. The patient has a central vein stent that would lead to jailing of the internal jugular vein.
16. The patient experiences angioplasty-induced venous rupture.
17. The patient has a flow limiting dissection after angioplasty.
18. The patient's hemodialysis access is thrombosed.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Percutaneous Transluminal Angioplasty (PTA) alone	PTA alone without use of the GORE VIABAHN	Intervention: Procedure: PTA alone without use of the GORE VIABAHN
PTA with covered stent	GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface	GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface

Primary Outcome Measures

Name	Time	Method
Primary patency at 3, 6, and 12 months	1 year	Target lesion primary patency at 3, 6, and 12 months

Secondary Outcome Measures

Name	Time	Method
Secondary patency at 3, 6, and 12 months	1 year	Target lesion secondary patency at 3, 6, and 12 months, access circuit primary and secondary patency at 3, 6, and 12 months, anatomic, clinical, and procedural success. Adverse events through 1 month

Trial Locations

Locations (3)

American Access Care of Queens; 🇺🇸 Flushing, New York, United States

American Access Care of Bronx; 🇺🇸 Bronx, New York, United States

Access Care Physicians of New York; 🇺🇸 White Plains, New York, United States